Fennec Pharmaceuticals Analyst Ratings
Fennec Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 112.23% | HC Wainwright & Co. | $18 → $17 | Maintains | Buy |
| 06/21/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 04/06/2023 | 99.75% | Cantor Fitzgerald | $12 → $16 | Maintains | Overweight |
| 04/04/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 03/31/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/26/2023 | 124.72% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 11/22/2022 | 49.81% | Cantor Fitzgerald | $9 → $12 | Upgrades | Neutral → Overweight |
| 10/20/2022 | 124.72% | HC Wainwright & Co. | $14 → $18 | Maintains | Buy |
| 09/26/2022 | 137.2% | Wedbush | $11 → $19 | Maintains | Outperform |
| 09/07/2022 | 37.33% | Capital One | → $11 | Initiates Coverage On | → Overweight |
| 08/08/2022 | 74.78% | Craig-Hallum | → $14 | Assumes | → Buy |
| 06/03/2021 | 74.78% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy |
| 04/21/2021 | 112.23% | Craig-Hallum | → $17 | Initiates Coverage On | → Buy |
| 04/19/2021 | 49.81% | Maxim Group | → $12 | Initiates Coverage On | → Buy |
| 06/05/2020 | 124.72% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 05/15/2020 | 87.27% | HC Wainwright & Co. | $17 → $15 | Reiterates | → Buy |
| 09/17/2018 | 99.75% | Wedbush | $17 → $16 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/04/2023 | 112.23% | HC Wainwright公司 | $18→$17 | 维护 | 买 |
| 2023年6月21日 | 124.72% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 04/06/2023 | 99.75% | 康托·菲茨杰拉德 | $12→$16 | 维护 | 超重 |
| 04/04/2023 | 124.72% | HC Wainwright公司 | →$18 | 重申 | →购买 |
| 03/31/2023 | 124.72% | HC Wainwright公司 | →$18 | 重申 | →购买 |
| 2023年1月26日 | 124.72% | HC Wainwright公司 | →$18 | 重申 | →购买 |
| 2022年11月22日 | 49.81% | 康托·菲茨杰拉德 | $9→$12 | 升级 | 中性→超重 |
| 10/20/2022 | 124.72% | HC Wainwright公司 | $14→$18 | 维护 | 买 |
| 09/26/2022 | 137.2% | 韦德布什 | $11→$19 | 维护 | 跑赢大盘 |
| 09/07/2022 | 37.33% | 大写一 | →$11 | 开始承保 | →超重 |
| 2022/08/08 | 74.78% | 克雷格-哈勒姆 | →$14 | 假设 | →购买 |
| 06/03/2021 | 74.78% | HC Wainwright公司 | $15→$14 | 维护 | 买 |
| 04/21/2021 | 112.23% | 克雷格-哈勒姆 | →$17 | 开始承保 | →购买 |
| 04/19/2021 | 49.81% | Maxim集团 | →$12 | 开始承保 | →购买 |
| 06/05/2020 | 124.72% | 康托·菲茨杰拉德 | →$18 | 开始承保 | →超重 |
| 2020/05/15 | 87.27% | HC Wainwright公司 | $17→$15 | 重申 | →购买 |
| 2018年09月17日 | 99.75% | 韦德布什 | $17→$16 | 维护 | 跑赢大盘 |
What is the target price for Fennec Pharmaceuticals (FENC)?
Fennec PharmPharmticals(FENC)的目标价是多少？
The latest price target for Fennec Pharmaceuticals (NASDAQ: FENC) was reported by HC Wainwright & Co. on August 4, 2023. The analyst firm set a price target for $17.00 expecting FENC to rise to within 12 months (a possible 112.23% upside). 11 analyst firms have reported ratings in the last year.
芬内克制药公司(纳斯达克代码：FENC)的最新目标价是由HC Wainwright&Co.于2023年8月4日报道的。这家分析公司将目标价定为17美元，预计FENC将在12个月内上涨至(可能上涨112.23%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for Fennec Pharmaceuticals (FENC)?
分析师对Fennec制药公司(FENC)的最新评级是多少？
The latest analyst rating for Fennec Pharmaceuticals (NASDAQ: FENC) was provided by HC Wainwright & Co., and Fennec Pharmaceuticals maintained their buy rating.
分析师对芬内克制药公司(纳斯达克代码：FENC)的最新评级由HC Wainwright&Co.提供，芬内克制药公司维持买入评级。
When is the next analyst rating going to be posted or updated for Fennec Pharmaceuticals (FENC)?
Fennec PharmPharmticals(FENC)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fennec Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fennec Pharmaceuticals was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Fennec制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Fennec制药的上一次评级是在2023年8月4日提交的，所以你应该预计下一次评级将在2024年8月4日左右的某个时候公布。
Is the Analyst Rating Fennec Pharmaceuticals (FENC) correct?
分析师对Fennec制药公司(FENC)的评级正确吗？
While ratings are subjective and will change, the latest Fennec Pharmaceuticals (FENC) rating was a maintained with a price target of $18.00 to $17.00. The current price Fennec Pharmaceuticals (FENC) is trading at is $8.01, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Fennec制药(FENC)评级维持不变，目标价在18.00美元至17.00美元之间。Fennec PharmPharmticals(FENC)目前的股价为8.01美元，超出了分析师的预测区间。